1. Home
  2. SAM vs BEAM Comparison

SAM vs BEAM Comparison

Compare SAM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$240.83

Market Cap

2.6B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$24.42

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAM
BEAM
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
SAM
BEAM
Price
$240.83
$24.42
Analyst Decision
Hold
Strong Buy
Analyst Count
10
14
Target Price
$227.44
$52.21
AVG Volume (30 Days)
115.4K
1.8M
Earning Date
04-23-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
95.45
82.31
EPS
9.89
N/A
Revenue
$1,964,994,000.00
$24,000.00
Revenue This Year
$1.02
N/A
Revenue Next Year
$1.31
$39.64
P/E Ratio
$24.29
N/A
Revenue Growth
N/A
33.33
52 Week Low
$186.72
$13.53
52 Week High
$260.00
$36.44

Technical Indicators

Market Signals
Indicator
SAM
BEAM
Relative Strength Index (RSI) 60.36 46.20
Support Level $211.05 $23.42
Resistance Level $252.33 $25.69
Average True Range (ATR) 7.70 1.32
MACD 1.07 0.04
Stochastic Oscillator 99.96 59.52

Price Performance

Historical Comparison
SAM
BEAM

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: